Zydus Cadila Gets USFDA Nod For Generic Antiviral Drug, Atazanavir Capsules
Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market Atazanavir capsules, an antiviral drug, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Atazanavir capsules in strengths of 150 mg, 200 mg and 300 mg, Zydus Cadila said in a statement.
Atazanavir, an antiretroviral drug, is used to treat Human Immunodeficiency Virus (HIV-1) infection incombination with other antiretroviral drugs.
The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
The Zydus Group now has 291 approvals and has so far filed over 390 abbreviated new drug application (ANDAs) since the commencement of the filing process in 2003-04, the company said.
Monzo Looks For US Banking License
Monzo is preparing a renewed push to secure a US banking licence, four years after abandoning its first attempt when tal... Read more
Crypto Firms Push Into US Banking
America’s cryptocurrency companies are scrambling to secure a foothold in the country’s traditional banking system, ... Read more
Parallel Banking: Stablecoins Are Now Global
Parallel Banking: How Stablecoins Are Building a New Global Payments SystemStablecoins—digital currencies pegged to tr... Read more
JPMorgan Deploys AI Chatbot To Revolutionize Research And Productivity
JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more
Private Equity And Banks: The Complex Web Of Leverage
Private equity has emerged as a significant force in the global financial landscape, driving substantial growth and inve... Read more
Financial Watchdog Highlights Unresolved Vulnerabilities In Shadow Banking Sector
The world’s leading financial stability watchdog has issued a warning about the unresolved vulnerabilities within the ... Read more